Post-hoc analyses showed GLP-1 RAs reduced major adverse cardiovascular events (MACE) and heart failure hospitalisation regardless of background SGLT2i use, and SGLT2i benefits were maintained with concomitant GLP-1 RAs. Here, GLP1R is linked to heart failure.